Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

British Journal of Haematology

Volumn 150, Issue 5, 2010, Pages 565-573

  D'Amore, Francesco ^a   Radford, John ^b   Relander, Thomas ^c   Jerkeman, Mats ^c   Tilly, Hervé ^d   Österborg, Anders ^e   Morschhauser, Franck ^f   Gramatzki, Martin ^g   Dreyling, Martin ^h   Bang, Bo ⁱ   Hagberg, Hans ^j  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CENTRE HENRI BECQUEREL   (France)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF KIEL   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ BISPEBJERG HOSPITAL   (Denmark)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

anaplastic; angioimmunoblastic; CD4; peripheral T cell lymphoma; zanolimumab

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MITOXANTRONE; PARACETAMOL; PREDNISONE; STEROID; VINCRISTINE; VINDESINE; ZANOLIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; ARTICLE; BRONCHITIS; BRONCHOSPASM; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CD4+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE SYNDROME; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY TYPE T CELL LYMPHOMA; FACE EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERPYREXIA; HYPOTENSION; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTICEMIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIREMIA; VOMITING; BLOOD; CHEMICALLY INDUCED; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; OPPORTUNISTIC INFECTION; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 77955800058     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08298.x     Document Type: Article

References (41)

1. Anderson, J.R., Armitage, J.O. Weisenburger, D.D. (1998) Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 9, 717 720.
2. Ansell, S.M., Horwitz, S.M., Engert, A., Khan, K.D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A. Borchmann, P. (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Journal of Clinical Oncology, 25, 2764 2769.
3. Armitage, J., Vose, J. Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology, 26, 4124 4130.
4. Chen, W., Kesler, M.V., Karandikar, N.J., McKenna, R.W. Kroft, S.H. (2006) Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry Part B: Clinical Cytometry, 70, 142 148.
5. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244 1253.
6. Coiffier, B., Brousse, N., Peuchmaur, M., Berger, F., Gisselbrecht, C., Bryon, P.A. Diebold, J. (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Annals of Oncology, 1, 45 50.
7. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
8. Dang, N.H., Pro, B., Hagemeister, F.B., Samaniego, F., Jones, D., Samuels, B.I., Rodriguez, M.A., Goy, A., Romaguera, J.E., McLaughlin, P., Tong, A.T., Turturro, F., Walker, P.L. Fayad, L. (2007) Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. British Journal of Haematology, 136, 439 447.
9. Dearden, C.E., Matutes, E. Catovsky, D. (2002) Alemtuzumab in T-cell malignancies. Medical Oncology, 19 (Suppl. S27 S32.
10. Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., Macdonald, A.P., Repp, R., Schetelig, J., Seipelt, G. Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 2920 2924.
11. Felgar, R.E., Salhany, K.E., Macon, W.R., Pietra, G.G. Kinney, M.C. (1999) The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Human Pathology, 30, 228 236.
12. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117 4126.
13. Fishwild, D.M., O'Donnell, S.L., Bengoechea, T., Hudson, D.V., Harding, F., Bernhard, S.L., Jones, D., Kay, R.M., Higging, K.M., Schramm, S.R. Lonberg, N. (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnology, 14, 845 851.
14. Gallamini, A., Stelitano, C., Calvi, R., Bellei, M., Mattei, D., Vitolo, U., Morabito, F., Martelli, M., Brusamolino, E., Iannitto, E., Zaja, F., Cortelazzo, S., Rigacci, L., Devizzi, L., Todeschini, G., Santini, G., Brugiatelli, M. Federico, M., Intergruppo Italiano Linfomi 2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood, 103, 2474 2479.
15. Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M.R., Tucci, A., Levis, A., Manna, A., Secondo, V., Rigacci, L., Pinto, A., Iannitto, E., Zoli, V., Torchio, P., Pileri, S. Tarella, C. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 2316 2323.
16. Gisselbrecht, C., Gaulard, P., Lepage, E., Coiffier, B., Brière, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, H., Berger, F., Bouhabdallah, R. Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood, 92, 76 82.
17. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121 3127.
18. Jaffe, E.S., Harris, N.L., Stein, H. Vardiman, J.W. (eds 2001) World Health Organization Classification of Tumours: Patholgy and Genetics of Tumours of Haematopietic and Lymphoid Tissues. IARC Press, Lyon.
19. Juco, J., Holden, J.T., Mann, K.P., Kelley, L.G. Li, S. (2003) Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. American Journal of Clinical Pathology, 119, 205 212.
20. Kim, Y.H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., Whittaker, S., Illidge, T.M., Schwarz, T., Kaufmann, R., Cooper, K., Knudsen, K.M., Lisby, S., Baadsgaard, O. Knox, S.J. (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 109, 4655 4662.
21. Kluin-Nelemans, H.C., Coenen, J.L., Boers, J.E., van Imhoff, G.W. Rosati, S. (2008) EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood, 112, 1039 1041.
22. Knox, S.J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., Wood, G.S., Hoppe, R., Abel, E.A., Steinman, L., Berger, R.G., Gaiser, C., Young, G., Bindl, J., Hanham, A. Reichert, T. (1991) Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood, 77, 20 30.
23. Knox, S., Hoppe, R.T., Maloney, D., Gibbs, I., Fowler, S., Marquez, C., Cornbleet, P.J. Levy, R. (1996) Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood, 87, 893 899.
24. Krenacs, L., Wellmann, A., Sorbara, L., Himmelmann, A.W., Bagdi, E., Jaffe, E.S. Raffeld, M. (1997) Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood, 89, 980 989.
25. Lopez-Guillermo, A., Cid, J., Salar, A., López, A., Montalbán, C., Castrillo, J.M., González, M., Ribera, J.M., Brunet, S., García-Conde, J., Fernández de Sevilla, A., Bosch, F. Montserrat, E. (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 9, 849 855.
26. Matutes, E., Coelho, E., Aguado, M.J., Morilla, R., Crawford, A., Owusu-Ankomah, K. Catovsky, D. (1996) Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis. Journal of Clinical Pathology, 49, 154 158.
27. Melnyk, A., Rodriguez, A., Pugh, W.C. Cabannillas, F. (1997) Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood, 89, 4514 4520.
28. Morabito, F., Gallamini, A., Stelitano, C., Callea, V., Guglielmi, C., Neri, S., Lazzaro, A., Orsucci, L., Ilariucci, F., Sacchi, S., Vitolo, U. Federico, M. (2004) Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer, 101, 1601 1608.
29. Morris, J.C., Waldmann, T.A. Janik, J.E. (2008) Receptor-directed therapy of T-cell leukemias and lymphomas. Journal of Immunotoxicology, 5, 235 248.
30. Morton, L.M., Wang, S.S., Devesa, S.S., Hartage, P., Weisenburger, D.D. Linest, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265 276.
31. O'Connor, O.A., Horwitz, S., Hamlin, P., Portlock, C., Moskowitz, C.H., Sarasohn, D., Neylon, E., Mastrella, J., Hamelers, R., Macgregor-Cortelli, B., Patterson, M., Seshan, V.E., Sirotnak, F., Fleisher, M., Mould, D.R., Saunders, M. Zelenetz, A.D. (2009) Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of Clinical Oncology, 27, 4357 4364.
32. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P. Nichols, J. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology, 19, 376 388.
33. Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. Loeffler, M., MabThera International Trial Group 2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379 391.
34. Ralfkiaer, E. (1991) Immunohistological markers for the diagnosis of cutaneous lymphomas. Seminars in Diagnostic Pathology, 8, 62 72.
35. Rider, D.A., Havenith, C.E., de Ridder, R., Schuurman, J., Favre, C., Cooper, J.C., Walker, S., Baadsgaard, O., Marschner, S., vandeWinkel, J.G., Cambier, J., Parren, P.W. Alexander, D.R. (2007) A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Research, 67, 9945 9953.
36. Rüdiger, T., Weisenburger, D.D., Anderson, J.R., Armitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F. Müller-Hermelink, H.K., Non-Hodgkin's Lymphoma Classification Project 2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 13, 140 149.
37. Talpur, R., Apisarnthanarax, N., Ward, S. Duvic, M. (2002) Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leukemia Lymphoma, 43, 121 126.
38. Weisel, K.C., Weidmann, E., Anagnostopoulos, I., Kanz, L., Pezzutto, A. Subklewe, M. (2008) Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. International Journal of Hematology, 88, 434 440.
39. Went, P., Agostinelli, C., Gallamini, A., Piccaluga, P.P., Ascani, S., Sabattini, E., Bacci, F., Falini, B., Motta, T., Paulli, M., Artusi, T., Piccioli, M., Zinzani, P.L. Pileri, S.A. (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. Journal of Clinical Oncology, 24, 2472 2479.
40. Woo, S., Gardner, E.R., Chen, X., Ockers, S.B., Baum, C.E., Sissung, T.M., Price, D.K., Frye, R., Piekarz, R.L., Bates, S.E. Figg, W.D. (2009) Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clinical Cancer Research, 15, 1496 1503.
41. Zaja, F., Russo, D., Silvestri, F., Fanin, R., Damiani, D., Infanti, L., Salmaso, F., Mariuzzi, L., Di Loreto, C. Baccarani, M. (1997) Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica, 82, 171 177.